{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:41:10Z","timestamp":1757706070639},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/crd.0000000000000023","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T14:35:00Z","timestamp":1394548500000},"page":"253-261","source":"Crossref","is-referenced-by-count":3,"title":["Anacetrapib"],"prefix":"10.1097","volume":"22","author":[{"given":"Lacey B.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210203","first-page":"e2","article-title":"Heart disease and stroke statistics-2012 update: a report from the American Heart Association.","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"R2-9-20210203","first-page":"1","article-title":"Deaths: leading causes for 2008.","volume":"60","author":"Heron","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"R3-9-20210203","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease.","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"R5-9-20210203","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R6-9-20210203","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-9-20210203","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-9-20210203","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R9-9-20210203","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"suppl","key":"R10-9-20210203","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport.","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"R11-9-20210203","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study.","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol"},{"key":"R12-9-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"R13-9-20210203","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(77)92274-7","article-title":"The Tromso Heart Study. High-density lipoprotein and coronary heart-disease: a prospective case-control study.","volume":"1","author":"Miller","year":"1977","journal-title":"Lancet"},{"key":"R14-9-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"R15-9-20210203","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"issue":"12A","key":"R16-9-20210203","doi-asserted-by":"crossref","first-page":"30N","DOI":"10.1016\/S0002-9149(01)02150-6","article-title":"Increasing high-density lipoprotein cholesterol: an update on fenofibrate.","volume":"88","author":"Despres","year":"2001","journal-title":"Am J Cardiol"},{"key":"R17-9-20210203","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11883-000-0093-1","article-title":"Mechanism of action of niacin on lipoprotein metabolism.","volume":"2","author":"Kamanna","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R18-9-20210203","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R20-9-20210203","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-9-20210203","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R22-9-20210203","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"R23-9-20210203","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R24-9-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2011.271","article-title":"Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.","volume":"91","author":"Gutstein","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R25-9-20210203","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm200484c","article-title":"Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.","volume":"54","author":"Smith","year":"2011","journal-title":"J Med Chem"},{"key":"R26-9-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ncpcardio0044","article-title":"Therapeutic approaches to raising plasma HDL-cholesterol levels.","volume":"1","author":"Thompson","year":"2004","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"suppl","key":"R27-9-20210203","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","article-title":"The metabolism and anti-atherogenic properties of HDL.","volume":"50","author":"Rye","year":"2009","journal-title":"J Lipid Res"},{"key":"R28-9-20210203","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4615-5901-6_9","article-title":"Lipoproteins and cellular cholesterol homeostasis.","volume":"28","author":"Johnson","year":"1997","journal-title":"Subcell Biochem"},{"key":"R29-9-20210203","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.bi.64.070195.001315","article-title":"Plasma lipid transfer proteins.","volume":"64","author":"Tall","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"R30-9-20210203","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cmet.2008.03.001","article-title":"HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.","volume":"7","author":"Tall","year":"2008","journal-title":"Cell Metab"},{"key":"R31-9-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/cr020466v","article-title":"HDL: the metabolism, function, and therapeutic importance.","volume":"104","author":"Wang","year":"2004","journal-title":"Chem Rev"},{"key":"R32-9-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ecl.2004.03.006","article-title":"Metabolic abnormalities: high-density lipoproteins.","volume":"33","author":"Barter","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R33-9-20210203","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"key":"R34-9-20210203","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1172\/JCI115532","article-title":"Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.","volume":"88","author":"Navab","year":"1991","journal-title":"J Clin Invest"},{"key":"R35-9-20210203","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL.","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ Res"},{"key":"R36-9-20210203","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/01.ATV.0000216600.37436.cf","article-title":"High-density lipoproteins enhance progenitor-mediated endothelium repair in mice.","volume":"26","author":"Tso","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R37-9-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.RES.0000199272.59432.5b","article-title":"High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I.","volume":"98","author":"Seetharam","year":"2006","journal-title":"Circ Res"},{"key":"R38-9-20210203","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/01.ATV.0000259299.38843.64","article-title":"Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis.","volume":"27","author":"Sumi","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R39-9-20210203","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/01.CIR.0000070934.69310.1A","article-title":"Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.","volume":"107","author":"Bisoendial","year":"2003","journal-title":"Circulation"},{"key":"R40-9-20210203","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0022-2275(20)31498-X","article-title":"Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis.","volume":"42","author":"Attie","year":"2001","journal-title":"J Lipid Res"},{"key":"R41-9-20210203","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0021-9258(18)61650-3","article-title":"Purification and characterization of a human plasma cholesteryl ester transfer protein.","volume":"262","author":"Hesler","year":"1987","journal-title":"J Biol Chem"},{"key":"R42-9-20210203","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","article-title":"Plasma cholesteryl ester transfer protein.","volume":"34","author":"Tall","year":"1993","journal-title":"J Lipid Res"},{"key":"R43-9-20210203","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.","volume":"53","author":"Barter","year":"2012","journal-title":"J Lipid Res"},{"key":"R44-9-20210203","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.pharmthera.2006.02.003","article-title":"Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.","volume":"111","author":"Chapman","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R45-9-20210203","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"R46-9-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"R47-9-20210203","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"},{"key":"R48-9-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(02)00327-1","article-title":"Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia.","volume":"166","author":"Maruyama","year":"2003","journal-title":"Atherosclerosis"},{"key":"R49-9-20210203","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1194\/jlr.M200024-JLR200","article-title":"Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay.","volume":"43","author":"Nagano","year":"2002","journal-title":"J Lipid Res"},{"key":"R50-9-20210203","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/iub.448","article-title":"Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles.","volume":"63","author":"Oliveira","year":"2011","journal-title":"IUBMB Life"},{"key":"R51-9-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0305-0491(82)90252-8","article-title":"Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species.","volume":"71","author":"Ha","year":"1982","journal-title":"Comp Biochem Physiol B"},{"key":"R52-9-20210203","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.ATV.6.3.345","article-title":"Increased lipid transfer activities in hyperlipidemic rabbit plasma.","volume":"6","author":"Son","year":"1986","journal-title":"Arteriosclerosis"},{"key":"R53-9-20210203","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1016\/S0021-9258(18)60692-1","article-title":"Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids.","volume":"263","author":"Swenson","year":"1988","journal-title":"J Biol Chem"},{"key":"R54-9-20210203","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","article-title":"Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.","volume":"48","author":"Morehouse","year":"2007","journal-title":"J Lipid Res"},{"key":"R55-9-20210203","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"R56-9-20210203","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R57-9-20210203","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1161\/01.ATV.0000243925.65265.3c","article-title":"Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE3-Leiden mice.","volume":"26","author":"Westerterp","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R58-9-20210203","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/01.ATV.19.4.1105","article-title":"Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.","volume":"19","author":"Plump","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R59-9-20210203","doi-asserted-by":"crossref","first-page":"36912","DOI":"10.1074\/jbc.274.52.36912","article-title":"Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.","volume":"274","author":"Foger","year":"1999","journal-title":"J Biol Chem"},{"key":"R60-9-20210203","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.ATV.0000080687.94313.67","article-title":"Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male dbdb mice.","volume":"23","author":"MacLean","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R61-9-20210203","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI118255","article-title":"Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.","volume":"96","author":"Hayek","year":"1995","journal-title":"J Clin Invest"},{"key":"R62-9-20210203","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"R63-9-20210203","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","article-title":"Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.","volume":"121","author":"Ritsch","year":"2010","journal-title":"Circulation"},{"key":"R64-9-20210203","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/eurheartj\/ehn465","article-title":"CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.","volume":"29","author":"Regieli","year":"2008","journal-title":"Eur Heart J"},{"key":"R65-9-20210203","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.109.872705","article-title":"Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.","volume":"120","author":"Vasan","year":"2009","journal-title":"Circulation"},{"key":"R66-9-20210203","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/01.ATV.20.5.1323","article-title":"Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.","volume":"20","author":"Ordovas","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R67-9-20210203","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.jacc.2012.07.045","article-title":"Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.","volume":"60","author":"Johannsen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R68-9-20210203","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1194\/jlr.M300520-JLR200","article-title":"A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly.","volume":"45","author":"Curb","year":"2004","journal-title":"J Lipid Res"},{"key":"R69-9-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2362.2004.01281.x","article-title":"Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).","volume":"34","author":"Klerkx","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R70-9-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","article-title":"Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Womens Genome Health Study.","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"R72-9-20210203","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"R73-9-20210203","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000141730.65972.95","article-title":"Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition): Norfolk population study.","volume":"110","author":"Boekholdt","year":"2004","journal-title":"Circulation"},{"key":"R74-9-20210203","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"R75-9-20210203","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1194\/jlr.M008706","article-title":"Modulating cholesteryl ester transfer protein activity maintains efficient pre--HDL formation and increases reverse cholesterol transport.","volume":"51","author":"Niesor","year":"2010","journal-title":"J Lipid Res"},{"key":"R76-9-20210203","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis.","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R77-9-20210203","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"R78-9-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"R79-9-20210203","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R80-9-20210203","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/CRD.0b013e31816a3b60","article-title":"HDL metabolism and CETP inhibition.","volume":"16","author":"Barkowski","year":"2008","journal-title":"Cardiol Rev"},{"key":"R82-9-20210203","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R83-9-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FJC.0b013e3181cf03cb","article-title":"Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.","volume":"55","author":"Connelly","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"R84-9-20210203","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"R85-9-20210203","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/HJH.0b013e32833b1f8e","article-title":"Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.","volume":"28","author":"Clerc","year":"2010","journal-title":"J Hypertens"},{"key":"R87-9-20210203","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/eurheartj\/ehp601","article-title":"Safety and tolerability of dalcetrapib (RO4607381JTT-705): results from a 48-week trial.","volume":"31","author":"Stein","year":"2010","journal-title":"Eur Heart J"},{"key":"R88-9-20210203","doi-asserted-by":"crossref","first-page":"39E","DOI":"10.1016\/j.amjcard.2009.09.018","article-title":"The effects of cholesterol ester transfer protein inhibition on cholesterol efflux.","volume":"104","author":"Tall","year":"2009","journal-title":"Am J Cardiol"},{"key":"R89-9-20210203","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.106.138347","article-title":"Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.","volume":"27","author":"Yvan-Charvet","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R90-9-20210203","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","article-title":"Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"R91-9-20210203","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.","volume":"33","author":"Luscher","year":"2012","journal-title":"Eur Heart J"},{"key":"R92-9-20210203","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"R93-9-20210203","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome.","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R94-9-20210203","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1194\/jlr.M007468","article-title":"Biochemical characterization of cholesteryl ester transfer protein inhibitors.","volume":"51","author":"Ranalletta","year":"2010","journal-title":"J Lipid Res"},{"key":"R95-9-20210203","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1124\/dmd.109.028704","article-title":"Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.","volume":"38","author":"Kumar","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R96-9-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/dmd.109.028696","article-title":"Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.","volume":"38","author":"Tan","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R97-9-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2125.2009.03465.x","article-title":"Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.","volume":"68","author":"Krishna","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R98-9-20210203","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/clpt.2008.109","article-title":"Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.","volume":"84","author":"Krishna","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R99-9-20210203","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ahj.2011.07.010","article-title":"Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.","volume":"162","author":"Dansky","year":"2011","journal-title":"Am Heart J"},{"key":"R100-9-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0091270008326718","article-title":"Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.","volume":"49","author":"Krishna","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R101-9-20210203","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2125.2009.03385.x","article-title":"Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.","volume":"67","author":"Krishna","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R102-9-20210203","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.2012.04171.x","article-title":"Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.","volume":"74","author":"Krishna","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R103-9-20210203","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/bdd.776","article-title":"Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.","volume":"32","author":"Krishna","year":"2011","journal-title":"Biopharm Drug Dispos"},{"key":"R104-9-20210203","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0091270010368676","article-title":"Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.","volume":"51","author":"Garg","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R105-9-20210203","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"R106-9-20210203","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease.","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R107-9-20210203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1208\/s12248-011-9254-0","article-title":"Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.","volume":"13","author":"Krishna","year":"2011","journal-title":"AAPS J"},{"key":"R108-9-20210203","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1194\/jlr.M016410","article-title":"Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.","volume":"52","author":"Castro-Perez","year":"2011","journal-title":"J Lipid Res"},{"key":"R109-9-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1194\/jlr.M018010","article-title":"Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.","volume":"53","author":"Krauss","year":"2012","journal-title":"J Lipid Res"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:08Z","timestamp":1620949748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201409000-00009"}},"subtitle":["A Potential New Therapy for Dyslipidemia"],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000023","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}